dipyridamole has been researched along with Erythema in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Requena, L | 1 |
FariƱa, C | 1 |
Barat, A | 1 |
1 other study available for dipyridamole and Erythema
Article | Year |
---|---|
Degos disease in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Atrophy; Cicatrix; Dipyridamole; Erythema; Homosexuality, Male; | 1998 |